Varian passes on an acquisition option as Augmenix closes a Series D funding round with $10.8 million raised in support of its Space OAR hydrogel for protecting the rectum during prostate radiation therapy.
Massachusetts-based Augmenix is hoping it can make it to the U.S. market with the $10.8 million funding round it just closed, the company said this month.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1uzNTeW
Cap comentari:
Publica un comentari a l'entrada